Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma.

Paweł SobczukMichał CholewińskiPiotr Lukasz Rutkowski

Published in: Expert opinion on pharmacotherapy (2024)

-mutant melanoma may benefit from TKI-based therapies. Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma.

Keyphrases

vascular endothelial growth factor
skin cancer
small molecule
chronic myeloid leukemia
high throughput
advanced non small cell lung cancer
single cell
epidermal growth factor receptor